Harvard Business Review

JUNE 6, 2011

5th Place: SmarterShade from Notre Dame created an elegant technology that adjusts the tint on windows, saving on building cooling costs by preventing heat gain. TNG Pharmaceuticals from University of Louisville developed a vaccine for a parasite that strikes cattle, costing the dairy and beef industry over $1 billion a year.

Pharmaceuticals 14

Pharmaceuticals Entrepreneur Industry Energy 14

Harvard Business Review

OCTOBER 23, 2014

Energy, agriculture, insurance, retail, human resources — no industry is unaffected. That’s why pharmaceutical, biotechnology, and medical device companies need to define their relevance in this new health care ecosystem, and soon. Or lenders’ enhanced abilities to gauge credit risk. They’re also sharing risk. But not for long.

Health Care 8

Health Care Pharmaceuticals Information Technology Supply Chain 8

Harvard Business Review

FEBRUARY 14, 2014

however improbably, into the world’s largest energy producer. Because of Kendall Square’s concentration of talent, and its infrastructure, Novartis, the giant Swiss pharmaceutical company, moved nearly its entire research center here from Switzerland. An Energy Bonanza . American creativity remains unsurpassed.

Chemicals 8

Chemicals Pharmaceuticals Energy Creativity 8

Harvard Business Review

MARCH 12, 2012

First, the company would increase the amount of free source material for its bio-fuel facility, which would lead to lower per-unit cost of bio-fuel energy, expediting a positive return on its investment. NWNA will benefit from lower manufacturing costs while also reducing its environmental footprint by collaborating with rivals.

Co-Opetition 14

Co-Opetition Company Brandenburger Game Theory 14

Harvard Business Review

JANUARY 31, 2013

First we see major shifts in demand: developing economies such as China and India are morphing from the world's source of low-cost manufacturing capacity to the world's best market opportunities. Pharmaceutical companies are mastering bio-engineering techniques that will help develop personalized medicines. but also the risks.

Globalization 8

Globalization Supply Chain Pharmaceuticals McKinsey 8

Harvard Business Review

APRIL 16, 2012

energy or telecom) or research-intensive industries (e.g., high technology or pharmaceutical) that are investing in projects with uncertain long-range payoffs. Strategic cash also can be used to finance long-term reinvestment programs in the business—which is especially valuable to companies in capital-intensive industries (e.g.,

Company 13

Company Cost of Capital Finance Long-term 13

Harvard Business Review

NOVEMBER 27, 2013

Recent events have seen a rash of the departures from large corporates: Steve Ballmer from MicroSoft, Jeremy Levin from Teva Pharmaceutical, and Thorsten Heins from Blackberry. After the initial rush of enthusiasm and energy, established routines and networks can smother the drive for innovation.

CEO 13

CEO Long-term Welch Pharmaceuticals 13

Harvard Business Review

JUNE 21, 2013

If, in addition, companies are managing their underperformers out poorly, the costs rise even further. food, beverage & tobacco, household and personal products); Energy & Utilities (e.g., pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g.,

Telecommunications 9

Telecommunications Health Care Talent Management Biotechnology 9

Harvard Business Review

MARCH 28, 2012

The Swiss pharmaceutical giant Roche is nothing if not determined in its quest to acquire Illumina, the San Diego-based leader in genetic-sequencing equipment. But acquisitions, unlike homegrown innovation, don't afford the luxury of multiple low-cost experiments — the sunk costs of an acquisition are too great.

Innovation 13

Innovation Company Biotechnology CFO 13

Harvard Business Review

FEBRUARY 15, 2012

For instance, shoe-manufacturer Guangzhou Constant has relocated its manufacturing facility to Yongzhou in Hunan, lured by tax breaks and by the prospect of wage costs that are between 15% and 20% lower. Some are shutting down because the companies that own them are going bankrupt, while other corporations are moving inland.

GDP 12

GDP Pharmaceuticals Long-term Globalization 12

Harvard Business Review

FEBRUARY 2, 2015

The factory floor at Pittsburgh’s Aquion Energy doesn’t look much like the steel mills that once populated this Rust Belt city. This is the kind of technology—and the type of firm—that will make renewable energy more efficient and more cost-effective. average (20%) of highly intensive STEM occupations.

Industry 8

Industry McKinsey Engineering Innovation 8

Harvard Business Review

SEPTEMBER 11, 2018

This phase involved a round of interviews with people at 28 organizations across a variety of sectors, including aviation, banking, pharmaceutical, professional services, and technology. Most of the changes we propose can be implemented without significant cost. Many were household names and leading global players in their sectors.

Career 12

Career Company Pharmaceuticals Long-term 12

Harvard Business Review

FEBRUARY 24, 2015

The diverging fortunes of two recent spin-offs in the energy industry illustrate how financial markets value autonomy from the parent. For example, after its spin-off from International Paper, Arizona Chemical drastically changed its market approach from a drive for volume to margin optimization.

Chemicals 8

Chemicals How To Kahneman Reputation 8

Harvard Business Review

FEBRUARY 22, 2017

food, beverage & tobacco, household and personal products); Energy & Utilities (e.g., pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., An IBM study estimated that the average cost of a data breach is around $4 million. ” A Real Strategic Threat.

Telecommunications 8

Telecommunications Health Care Contingency Plans Biotechnology 8

Harvard Business Review

SEPTEMBER 15, 2014

As Linda Hill and her colleagues have described, the company needed expert knowledge as it navigated the technically and ethically challenging waters of pharmaceutical development and marketing. The more responsible participants feel, the more energy and drive they’ll offer — and the better they’ll feel about participating.

Gilbert 9

Gilbert Participative Cooper Network Economy 9

Harvard Business Review

SEPTEMBER 14, 2011

We recently visited the brand-new R&D lab of Dr Reddy's , one of India's leading pharmaceutical firms. Dr Reddy's plan is to leverage Chirotech's scientific capabilities to optimize drug development processes, thus lowering manufacturing costs and speeding time-to-market. Cambridge, U.K. facility in Cambridge Science Park.

Globalization 9

Globalization Innovation Decentralization Chemicals 9

Harvard Business Review

APRIL 13, 2015

Meanwhile, sensor technology is both proliferating and dropping in cost, allowing the types of data captured by businesses to become ever more contextually relevant. And finally, the cost of data storage continues to plummet, allowing businesses to store everything they might need to make a wide variety of predictions. Scalable Niches.

Software 8

Software Trends Mass Marketing Marketing 8

Harvard Business Review

MAY 16, 2011

Catchlight Energy , their 50/50 joint venture, draws on technical resources and existing operations of the two partners. Most major pharmaceutical companies are well-known for their joint R&D deals with biotech start-ups. Google uses a different approach to working with multiple external parties.

Software 15

Software Licensing Long-term Telecommunications 15

Harvard Business Review

APRIL 22, 2013

Most of us think of biotech as the province of multinational pharmaceutical corporations and well-funded ventures, but the founders of BioCurious believe (as they say in their mission statement) "that innovations in biology should be accessible, affordable, and open to everyone." Socialize your underused assets.

Mission Statement 9

Mission Statement Class Learning-by-Doing Pharmaceuticals 9

Harvard Business Review

MARCH 1, 2012

Hospira began life when Abbott Laboratories spun off its production division, and it is now the world leader in the production of injectable pharmaceuticals. The growth of CMOs in high-tech fields such as alternative energy and integrated photonics would be a significant boost to the U.S. First, that means tax incentives.

Contract Manufacturing 9

Contract Manufacturing Offshoring Supply Chain Biotechnology 9

Harvard Business Review

OCTOBER 22, 2013

Let’s say you’re in the energy sector. Cosmeceuticals , for example, is the new industry emerging from the convergence of the personal care/cosmetic and pharmaceutical industries. Frugal innovations require frugal thinking — an ability to engineer cost?conscious Think Frugally.

Skills 8

Skills Power Six Sigma Disruptive Innovation 8

Harvard Business Review

JUNE 16, 2016

The Joint Center For Energy Storage Research (JCESR) has a five-year mandate to develop next generation battery technologies. In battery research, for example, scientists have long focused on finding materials with greater energy density. Draetta of IACS has found many of the same issues arise in pharmaceutical research.

Technology 8

Technology Venture Capitalist Supply Chain Innovation 8

Harvard Business Review

OCTOBER 28, 2013

Lois Kelly, co-author with Carmen Medina (see case study #1) of the upcoming book, Rebels at Work: Befriending the Bureaucratic Black Belts and Leading Change from Within , says the smartest people carefully calculate what’s worth their time and energy. There are costs to going against the grain so you need to be sure it’s worth it.

How To 11

How To Case Study Politics Reputation 11

Harvard Business Review

DECEMBER 5, 2016

Japanese pharmaceutical Eisai used them to improve care for Alzheimer’s patients. And the cost was marginal. The project released staff energy that was more than ready to be tapped. Innovation communities had been used by Best Buy to grow its portion of the women’s consumer electronics market by $4.4b

Library 8

Library Strategy Reference Bottom-up 8

Harvard Business Review

OCTOBER 27, 2014

I studied large-scale change and innovation efforts in 56 randomly selected companies in the high-tech, retail, pharmaceutical, banking, automotive, insurance, energy, non-profit, and health care industries. In the space of a year, the company cut costs by nearly $1 million. Taylor imbued the process with his own urgent pace.

Middle Management 13

Middle Management Six Sigma Taylorism Taylor 13

Harvard Business Review

NOVEMBER 20, 2015

But entrepreneurial know-how and energy can work very effectively in the context of plugging-in as a supplier, as Steve Cronce and thousands of others are learning. Taking this path isn’t a cake walk, however. Jorge Rodriguez-Gonzalez, founder of PACIV in Puerto Rico, flipped this dynamic on its head.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

MAY 28, 2013

Not rising costs. food, beverage & tobacco, household and personal products); Energy & Utilities (e.g., pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., And what did they say was their biggest concern? Not competitive threats.

Talent Management 8

Talent Management Company Telecommunications Management 8

Harvard Business Review

SEPTEMBER 20, 2011

One obvious reason was that the huge trillion-dollar investment bets, most of it taxpayer money, in synthetic biology, robotics, nanotechnogy, space, and alternative energy did not pay off. The Corporate Elite continued to do what they did most of their careers: increase efficiencies, boost scale, and lower costs to maximize profits.

Innovation 12

Innovation Supply Chain Offshoring Policies 12

Skip Prichard

JANUARY 14, 2021

“Maximizing shareholder value at the cost of everything and everyone else is a bankrupt enterprise.” These two factors have made everyone aware that maximizing shareholder value at the cost of everything and everyone else is a bankrupt enterprise. Erich is the founder of VIVALDI, a global strategy and transformation firm.

Brand 96

Brand Insurance Participative Open-book 96

Harvard Business Review

APRIL 19, 2016

In virtually every advanced field, whether it’s information technology, biotechnology, agriculture, or renewable energy, America holds a leading position. In the pharmaceutical industry, the monitoring process can be incredibly elaborate. Since World War II, the U.S. has been an innovation superpower.

Innovation 8

Innovation Company Competitive Advantage Venture Funding 8

Harvard Business Review

NOVEMBER 3, 2017

” Consider the experience of a major utility that made the strategic decision to undertake a broad-based initiative aimed at improving efficiency and reining in costs. When a detailed cost assessment identified significant savings potential, executive leadership boldly added another five percentage points to the target.

Execution 13

Execution Strategy Decentralization Short-term 13

Harvard Business Review

NOVEMBER 20, 2012

Michael Porter, the godfather of business strategy, has gotten a lot of attention lately for trying to apply his model of competitive dynamics to the current plight of the United States — high unemployment, crushing healthcare costs, crumbling infrastructure, and widespread indebtedness.

Porter 15

Porter Globalization Supply Chain Politics 15

Harvard Business Review

JANUARY 31, 2011

For instance, during the 1990s, China became a low-cost producer of computer hardware (much of which was designed in the U.S.). We find ourselves falling behind in several industries of the future, including solar energy and other areas of green tech. Let's remember that international trade is not a zero-sum game. productivity.

Real Estate 14

Real Estate Policies Telecommunications Industry 14

Harvard Business Review

JUNE 20, 2017

This would amount to higher tariffs for inputs or final goods, which, though unlikely to reach the 25% tariff levels suggested during Trump’s campaign, would still raise costs for multinationals and further inhibit cross-national supply chain integration. market but also as a priority market in their global portfolios.

Supply Chain 8

Supply Chain Depreciation Uncertainty Marketing 8

Harvard Business Review

AUGUST 23, 2016

Boards of companies operating in the consumer discretionary industry have a disproportionately high representation of Democrats, while boards operating in the industrials and energy and utilities industries skew more Republican. food, beverage & tobacco, household and personal products); Energy & Utilities (e.g.,

Politics 8

Politics Committee Telecommunications Diversity 8